Cargando…

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK(-) ALCL vs. CD30(high) PTCL, NOS

AIMS: The differential diagnosis between ALK-negative anaplastic large cell lymphoma (ALK(-) ALCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) with high expression of CD30 (CD30(high)) are essential. However, no reliable biomarker is available in daily practice except CD30. S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Chenxi, Wu, Wanna, Fan, Meiting, Wang, Zhen, Feng, Xiaoli, Liu, Cuiling, Liu, Jia, Liu, Guangzhen, Xia, Lei, Si, Haipeng, Gu, Ying, Liu, Nian, Luo, Dan, Wang, Yubo, Ma, Dongshen, Hu, Shimin, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303105/ https://www.ncbi.nlm.nih.gov/pubmed/37388733 http://dx.doi.org/10.3389/fimmu.2023.1132834

Ejemplares similares

STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(−) ALCL
por: Andersson, Emma I., et al.
Publicado: (2020)

PTCL, NOS: An update on classification, risk-stratification, and treatment
por: Weiss, Jonathan, et al.
Publicado: (2023)

The heterogeneous landscape of ALK negative ALCL
por: Mereu, Elisabetta, et al.
Publicado: (2017)

Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS
por: Cutucache, Christine E., et al.
Publicado: (2016)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
por: Miyawaki, Kohta, et al.
Publicado: (2022)

Agent Repurposing for the Treatment of Advanced Stage Diffuse Large B-Cell Lymphoma Based on Gene Expression and Network Perturbation Analysis
por: Xiang, Chenxi, et al.
Publicado: (2021)

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
por: Hare, Lucy, et al.
Publicado: (2021)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
por: Popova, Tanya Naskova, et al.
Publicado: (2018)

Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category
por: Sakata-Yanagimoto, Mamiko, et al.
Publicado: (2021)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review
por: Sueyasu, Takuto, et al.
Publicado: (2018)

Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs
por: Pearson, Joel D, et al.
Publicado: (2014)

Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy
por: Ohara, Masahiro, et al.
Publicado: (2017)

Editorial: PTCL from genes to therapy
por: Janikova, Andrea
Publicado: (2022)

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
por: Wai, Cho Mar Myint, et al.
Publicado: (2022)

Erratum to: ‘Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs’
por: Pearson, Jodel D., et al.
Publicado: (2016)

Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)
por: Eisfeld, Hannah, et al.
Publicado: (2020)

Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network
por: Federico, Massimo, et al.
Publicado: (2018)

The Dual Role of Autophagy in Crizotinib-Treated ALK(+) ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
por: Espinos, Estelle, et al.
Publicado: (2021)

The DNA-helicase HELLS drives ALK(−) ALCL proliferation by the transcriptional control of a cytokinesis-related program
por: Tameni, Annalisa, et al.
Publicado: (2021)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
por: Maura, Francesco, et al.
Publicado: (2020)

Next-Generation Sequencing Identifies Deregulation of MicroRNAs Involved in Both Innate and Adaptive Immune Response in ALK+ ALCL
por: Steinhilber, Julia, et al.
Publicado: (2015)

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK(+) ALCL: results of COG trial ANHL12P1
por: Lowe, Eric J., et al.
Publicado: (2021)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage
por: Sun, Qi, et al.
Publicado: (2022)

Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx
por: Ma, Dongshen, et al.
Publicado: (2022)

The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)
por: Zhang, Yafei, et al.
Publicado: (2021)

BIA-ALCL-Horizon Scanning
por: Mallucci, Patrick, et al.
Publicado: (2022)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Identification of C/EBPβ Target Genes in ALK+ Anaplastic Large Cell Lymphoma (ALCL) by Gene Expression Profiling and Chromatin Immunoprecipitation
por: Bonzheim, Irina, et al.
Publicado: (2013)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021)

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL
por: Montes-Mojarro, Ivonne-Aidee, et al.
Publicado: (2022)

Isolated hypoglossal nerve palsy as a presenting symptom of metastatic peripheral T-cell lymphoma – not otherwise specified (PTCL–NOS): a unique case & a review of the literature
por: Bryer, Emily, et al.
Publicado: (2018)

How molecular advances may improve the diagnosis and management of PTCL patients
por: Drieux, Fanny, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u1favo3u4qpp6mukvvo5cc34po